Evidence map›Paper›PMID 38494257›Full record

ArticleJournal, genetic engineering & biotechnology2024

Identification of cuproptosis-related lncRNAs signature for predicting the prognosis in patients with kidney renal clear cell carcinoma.

Ya He, Hongxia Zhang, Jingang Li, Hui Zhou, Fei Wang, Guangliang Zhang, Yuetao Wen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal, genetic engineering & biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ya HeDepartment of Physical Examination Center, Chongqing University Jiangjin Hospital, School of Medicine, Chongqing University, Chongqing, China.
Hongxia ZhangDepartment of Neurosurgery, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
Jingang LiDepartment of Neurosurgery, Chongqing University Jiangjin Hospital, School of Medicine, Chongqing University, Chongqing, China.
Hui ZhouDepartment of Neurosurgery, Chongqing University Jiangjin Hospital, School of Medicine, Chongqing University, Chongqing, China.
Fei WangDepartment of Neurosurgery, Chongqing University Jiangjin Hospital, School of Medicine, Chongqing University, Chongqing, China.
Guangliang ZhangDepartment of Neurosurgery, Chongqing University Jiangjin Hospital, School of Medicine, Chongqing University, Chongqing, China.
Yuetao WenDepartment of Neurosurgery, Chongqing University Jiangjin Hospital, School of Medicine, Chongqing University, Chongqing, China. Electronic address: wenyuetao@cqu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKidney renal clear cell carcinoma (KIRC), with low survival rate, is the most frequent subtype of renal cell carcinoma. Recently, more and more studies indicate that cuproptosis-related genes (CRGs) and long non-coding RNAs (lncRNAs) play a vital role in the occurrence and development of many types of cancers. However, the roles of cuproptosis-related lncRNAs (CRlncRNAs) in the KIRC was uncertain.

resultsIn our study, CRlncRNAs were obtained by coexpression between differentially expressed and prognostic CRGs and differentially expressed and prognostic lncRNAs, and an 8-CRlncRNAs (AC007743.1, AC022915.1, AP005136.4, APCDD1L-DT, HAGLR, LINC02027, MANCR and SMARCA5-AS1) risk model was established according to least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression. This risk model could differentiate immune cell infiltration, immune function and gene mutation.

conclusionsThis 8-CRlncRNAs risk model may be promising for the clinical prediction of prognoses, tumor immune, immunotherapy response and chemotherapeutic response in KIRC patients.

Indexed as

CuproptosisCuproptosis-related lncRNAsKidney renal clear cell carcinomaTumor immune

Identifiers

PMID38494257
PMCPMC10860879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.